# Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

> **NCT01275131** · PHASE1 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin aspart
- **DRUG:** Recombinant human hyaluronidase PH20 (rHuPH20)

## Key facts

- **NCT ID:** NCT01275131
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275131, "Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01275131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*